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Summary
 
Evidence has been accumulating that shows that insulin-dependent diabetes is subject to im-
munoregulation. To determine whether cytotoxic T lymphocyte–associated antigen 4 (CTLA-4)
is involved, we injected anti–CTLA-4 mAb into a TCR transgenic model of diabetes at differ-
ent stages of disease. When injected into young mice, months before they would normally be-
come diabetic, anti–CTLA-4 induced diabetes rapidly and essentially universally; this was not
the result of a global activation of T lymphocytes, but did reflect a much more aggressive T cell
infiltrate in the pancreatic islets. These effects were only observed if anti–CTLA-4 was injected
during a narrow time window, before the initiation of insulitis. Thus, engagement of CTLA-4
at the time when potentially diabetogenic T cells are first activated is a pivotal event; if engage-
ment is permitted, invasion of the islets occurs, but remains quite innocuous for months, if not,
insulitis is much more aggressive, and diabetes quickly ensues.
 
I
 
nsulin-dependent diabetes mellitus (IDDM) is a highly
regulated autoimmune disease, certainly in mice and prob-
ably in humans (1, 2). Three major phases of disease can be
distinguished: the generation of T lymphocytes potentially
reactive to proteins made by pancreatic islet 
 
b
 
 cells, infiltra-
tion of these cells and other leukocytes into the islets, and
the terminal destruction of 
 
b
 
 cells leading to hyperglyce-
mia. Progression from one stage to the next is neither auto-
matic nor immediate. The nonobese diabetic (NOD) mouse
has been instrumental in defining these three disease phases,
but they are even more clear in the BDC2.5 TCR trans-
genic (tg) model of diabetes (3). BDC2.5 tgs carry the re-
arranged TCR genes from a CD4
 
1
 
, 
 
b
 
 cell–specific, diabe-
togenic T cell clone isolated from an NOD mouse (4).
Despite their autoreactivity, T cells expressing the trans-
gene-encoded specificity escape clonal deletion and make
an exaggerated contribution to the peripheral T cell reper-
toire. In BDC2.5 mice on the NOD genetic background,
the autoreactive cells appear inert during the animals’ first
weeks and begin to infiltrate the islets shortly after 2 wk of
age, but do not provoke diabetes until several months later
(3); in mice on the C57Bl/6 (B6) background, the delay
between the onset of insulitis and diabetes is shortened to
weeks (5). The nature of the cells and molecules modulat-
ing the initiation of insulitis and evolution to diabetes has
been the subject of much discussion (6).
One molecule that makes an attractive candidate as a di-
abetes regulator is cytotoxic T lymphocyte–associated anti-
gen 4 (CTLA-4; CD152; 7–9). This Ig superfamily mem-
ber shares many features with the CD28 molecule; the two
have marked structural homology, their expression is restricted
to T cells, they both bind to B7-1 and B7-2. CD28 is the
prototypical T cell costimulator, transmitting a positive signal
that synergizes with the signal delivered through the TCR
to promote optimum activation. Some reports (10, 11) have
suggested that CTLA-4 has an analogous function as a sec-
ondary costimulator; however, others have argued for an
opposing role, as a dampener of T cell activation. CTLA-4
blockade enhances T cell responses in vitro (12–15) and in
vivo (16, 17), augments antitumor immunity (18), and exac-
erbates an induced autoimmune disease (19, 20). In addi-
tion, mice unable to express CTLA-4 due to an engineered
null mutation show massive accumulation of activated T
cells in the peripheral lymphoid organs and leukocyte infil-
tration into a variety of tissues (21, 22). Earlier studies em-
phasized a role for CTLA-4 in downmodulating an ongo-
ing T cell response, but more recent experiments point to
an alternative or additional influence on the initial charac-
ter of the response (8, 9). A nice example of an early role is
the recent report that anti–CTLA-4 mAb can prevent tol-
erance induction and promote an abortive response if ad-
ministered together with a normally tolerogenic stimulus (23).
Clearly, then, CTLA-4 is an important regulator of the
immune response, exerting its influence on reactivity to
both foreign and self antigens. There are two hints that it
might be involved in regulating the progression of insulin-
dependent diabetes mellitus. First, one of the human diabe-
tes susceptibility loci encompasses the CD28 and CTLA-4
  
428
 
Regulation of Diabetes Progression by CTLA-4
 
genes (24), as does one of the loci modulating diabetes in
BDC2.5 TCR tg mice (5). Second, reagents that block B7-1
and/or B7-2 had clear, though complicated, effects on dis-
ease in NOD mice (25). Unfortunately, in neither of these
cases was it possible to distinguish an effect promoted by
CD28 from one mediated by CTLA-4.
Our strategy to evaluate the influence of CTLA-4 on the
unfolding of diabetes was to inject an anti–CTLA-4 mAb
into BDC2.5 TCR tg mice at different ages. Such an ap-
proach was appealing for a number of reasons. The major
advantages of generating a CTLA-4 deficiency by means of
an mAb rather than a null mutation were that we could in-
tervene at will during the different phases of disease, and
were more likely to avoid physiological adaptations to the
absence of CTLA-4. Among the advantages of studying the
TCR tg model rather than standard NOD mice were that
the three disease phases are more precisely defined and syn-
chronized in the former, and that it would be easier to vi-
sualize effects on the actual pathogenic T cells. This strat-
egy revealed an important role for CTLA-4 in controlling
diabetes progression.
 
Materials and Methods
 
Diabetes and Insulitis.
 
BDC2.5 TCR tg mice (3) backcrossed
onto the NOD genetic background for 16 or 17 generations were
housed in our conventional facility. Mice were followed for dia-
betes daily for 2 wk after the last mAb injection, twice a week for
another 2 wk, and weekly thereafter, quantitating urine glucose
levels and confirming positives by blood glucose measurements
(3). Hematoxylin–eosin staining of thin sections from Bouin’s so-
lution–fixed, paraffin-embedded pancreata was performed as de-
scribed (26). Multiple sections from each animal were scored for
insulitis, at least 40 islets per individual.
 
Antibodies and Flow Cytometry.
 
For the injections, the anti–
CTLA-4 mAbs 9H10 (13) and UC10-4F10-11 (reference 12;
PharMingen, San Diego, CA), the anti-CD28 mAb 37N51.1 (27),
and, as controls, the irrelevant hamster antibodies F536 (13) or
G235-2356 (anti-TNP) (PharMingen) were used. The following
mAbs were used for T cell analysis: phycoerythrin-conjugated anti-
CD4 (Caltag Labs., South San Francisco, CA); biotin-conjugated
anti-CD8 (Caltag Labs.); FITC-conjugated anti-CD69 (Phar-
Mingen); IM7, specific for CD44; Mel-14, specific for CD62L;
and PC61, specific for CD25 (3). Biotinylated antibody was re-
vealed with Cy5-labeled streptavidin (Jackson ImmunoResearch,
West Grove, PA), and the other antibodies either with Texas red–
labeled anti–rat IgG (Jackson ImmunoResearch) or FITC-labeled
anti–rat IgG (Caltag Labs.). 
Immunostainings and analyses were performed essentially as
described (28). Pancreatic T cells were extracted by gently teasing
the pancreas in a small volume of medium on ice (after the pan-
creatic lymph nodes were carefully removed); due to the young
age of the mice and the aggressive nature of the insulitis, it was
not possible to isolate islets.
 
Results
 
Treatment with Anti–CTLA-4, but Not Anti-CD28, Pre-
cipitates Diabetes in Young BDC2.5/NOD tgs.
 
We began by
probing CTLA-4 function at disease onset in BDC2.5
TCR tg mice carried on the NOD genetic background.
The first sign of disease in these animals is an impressive in-
sulitis beginning after about 15 d of age (3). We injected
anti–CTLA-4, anti-CD28, or control mAb on days 9, 12,
and 15, a protocol analogous to one that was effective at
modulating antitumor responses (18). As indicated in Fig. 1,
diabetes was rapidly precipitated in almost all of the tgs treated
with anti–CTLA-4. Compared with unmanipulated BDC2.5/
NOD mice, this represents a striking increase in both the
time of onset (in comparison with the usual 5–6 mo) and
incidence (compared with the typical 15–30%). Diabetes
was not provoked prematurely by treatment with either the
anti-CD28 or control mAbs.
 
Anti–CTLA-4 mAb Is Diabetogenic only when Present before
the Initiation of Insulitis.
 
Next, we explored the influence
of CTLA-4 on disease progression by varying the time of
anti–CTLA-4 mAb injection. As illustrated in Fig. 2 
 
A
 
,
only those animals that got anti–CTLA-4 on or before day
12 exhibited premature diabetes. Interestingly, no matter
when the first dose of mAb was administered, anywhere
from days 2 to 12, hyperglycemia was not detectable until
17 d of age. When the initial anti–CTLA-4 injection was
given on day 17 or later, diabetes was not induced. Initiat-
ing the treatment at much later times, e.g., at 10 wk of age,
also had no effect (data not shown).
As mentioned above, one advantage of working with the
BDC2.5 TCR tg model is that early disease events are
more synchronous than in NOD mice, in particular, the
initiation of insulitis, which occurs over about a week in
individual BDC2.5 tgs but can be scattered over many
weeks in NOD animals. Thus, we could more precisely
correlate the window of anti–CTLA-4 efficacity with the
development of insulitis. A comparison of 
 
A
 
 and 
 
B
 
 of Fig.
2 reveals that anti–CTLA-4 mAb had to be present before
the initiation of insulitis to provoke premature diabetes.
 
Anti–CTLA-4 Treatment Dramatically Alters the Aggressive-
ness, but Not the Timing, of Insulitis.
 
We also looked for more
immediate alterations in the phenotype or behavior of T
cells as a result of the anti–CTLA-4 treatment. Fig. 3 
 
A
Figure 1. Treatment with anti–CTLA-4 mAb provokes a rapid onset
of diabetes. BDC2.5/NOD mice were injected intraperitoneally with
anti–CTLA-4, anti-CD28, or control mAb at 9, 12, and 15 d of age (total
dose: 250–300 mg). 
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compares the expression of activation markers on CD4
 
1
 
 T
cells from 17-d-old mice administered control mAb or
anti–CTLA-4 before the initiation of insulitis. Few cells
from the peripheral lymphoid organs of control mAb-
injected animals expressed the early activation markers
CD69 and CD25 (the latter not shown); however, a signif-
icant fraction displayed late activation markers indicative of
chronically activated or memory cells, i.e., low levels of
CD62L and high levels of CD44 (the latter not shown);
many more of the cells isolated from the pancreatic lesion
expressed these early and late activation markers. The pro-
files from the different tissues of animals injected with anti–
CTLA-4 were analogous, notably the differences between
the pancreas and the lymphoid tissues. By this measure,
then, the anti–CTLA-4 treatment did not alter the activa-
tion state of the bulk of CD4
 
1
 
 T cells, either systemically
or locally, within the pancreas. Nor did the treatment pro-
voke a generalized inflammatory response (reflecting the
phenotype of the CTLA-4–null mice; references 21, 22).
We observed no infiltrates in the heart, lung, liver, kidney,
brain, gut, or spleen on day 17 of age after having injected
the mAb according to diverse protocols (data not shown).
Fig. 3 
 
B
 
 compares T cell invasiveness in BDC2.5 tgs
administered control mAb or anti–CTLA-4 well before in-
sulitis initiation. The kinetics of insulitis in the two types of
animals appeared the same; there was no infiltrate seen at
11 d and a substantial one at 17 d. However, the nature of
the insulitis was strikingly different in the two cases. In
control mAb-injected mice, the invading cells penetrated
the islets, but rested at the outskirts, quite segregated from
the 
 
b
 
 cell mass. This picture is typical of insulitis in
BDC2.5/NOD tgs. The mice injected with anti–CTLA-4
exhibited a much more aggressive infiltrate, with complete
intermingling of the invading leukocytes and the 
 
b
 
 cells,
even spilling out into the exocrine tissue, and marked
edema. This aggressive image is reminiscent of insulitis in
BDC2.5/NOD tgs just after cyclophosphamide injection
(6), young BDC2.5/B6 mice (5), and neonatal NOD mice
transferred with activated BDC2.5 T cells (29).
 
Discussion
 
Our data indicate that CTLA-4 plays a pivotal role at
disease onset in the BDC2.5/NOD TCR tg model of dia-
betes. Whether or not CTLA-4 can be engaged on the T cells
of animals 12 d old or less conditions the nature of the in-
sulitis that ensues, how aggressive it looks and how rapidly
it evolves to full-blown diabetes. We do not know pre-
cisely what happens to BDC2.5 T cells during the animals’
first days of life other than that they are generated in the
thymus and populate the peripheral lymphoid organs. Pre-
sumably, they must encounter the relevant 
 
b
 
 cell antigen,
become activated, and migrate to the islets, but the order
and details of these events have not yet been established.
Whatever the precise scenario turns out to be, it must in-
clude an opportunity for CTLA-4 to be engaged by its
ligand and to exert its influence on the nature of insulitis.
CTLA-4’s role in BDC2.5/NOD mice appeared to be
confined to disease onset. Anti–CTLA-4 mAb precipitated
diabetes when administered before insulitis began, but never
afterwards. The opposite is true with cyclophosphamide;
this drug rapidly induces diabetes in BDC2.5/NOD ani-
mals, but only in those which already exhibit insulitis (6).
The effect of cyclophosphamide indicates that the nonde-
structive form of insulitis is certainly not refractory to in-
citement. It seems, then, that preempting the engagement
of CTLA-4 can alter disease course in the BDC2.5 model,
but annulling the engagement cannot. CTLA-4 seems to
control entry into a state of stable and balanced autoimmu-
nity; once this state is established, mechanisms independent
of CTLA-4 must maintain it. Such a restricted window of
influence would not have been expected according to the
original idea of CTLA-4 function, i.e., that it is critical for
the downmodulation of an ongoing T cell response. How-
ever, it fits very well with the newer notion that CTLA-4
can be important in setting, at the time of initiation, the
timbre of a response (15, 30).
How might CTLA-4 engagement when BDC2.5 T cells
first encounter their antigen influence the nature of the
Figure 2. Anti–CTLA-4 treatment works only when first administered
before the initiation of insulitis. (A) BDC2.5/NOD mice were treated with
anti–CTLA-4 mAb using a variety of protocols. All received a total dose
of 250–300 mg, except those injected only on day 12, which got 200 mg.
The day on which the mAb was first administered is indicated. Carrots, in-
dividual injections; stippling, the presence of anti–CTLA-4; solid black, the
cumulative frequency of diabetes. The numbers to the right represent the
final frequency of diabetics. All experiments included anti-CD28 and/or
irrelevant mAb controls. In several experiments, paired littermates re-
ceived earlier (before 12 d) or later (after 17 d) injections. (B) Groups of
BDC2.5/NOD mice were killed at different ages, and insulitis quanti-
tated. Each bar represents the average proportion of infiltrated islets (groups
of 5–12 mice). The horizontal scale (days of age) matches that of A. 
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insulitis that develops? It is well established that CD28 trans-
mits a supplementary positive signal when engaged to-
gether with the TCR; such costimulation augments the
production of IL-2, expression of the IL-2 receptor, and
proliferation, and is required for most, though not all, T
cell responses to reach fruition (8, 9). There is now strong
evidence that engagement of CTLA-4, along with CD28
and the TCR, relays a negative signal (31), dampening T
cell responses by reducing levels of IL-2, IL-2 receptor, and
proliferation (14, 15, 23). The ultimate result can be func-
tional nonresponsiveness, even if some signs of activation
are still evident (23). In the case of BDC2.5 tgs, CTLA-4
engagement permits activation and mobilization of the 
 
b
 
cell–reactive T cells, as evidenced by the strong islet infil-
trate that develops, but it clearly alters the quality of the re-
sponse since the insulitis appears less aggressive and does
not provoke the destruction of 
 
b
 
 cells until after a long de-
lay. The exact phenotypic alterations that CTLA-4 engage-
ment induces in responding to BDC2.5 T cells remain to
be identified. It is possible that the production of inflamma-
tory cytokines is attenuated, that the ratio of T helper phe-
notypes is skewed against cells that destroy 
 
b
 
 cells or to-
wards protective cells, or that other effector functions are
compromised. Functional nonresponsiveness is also a possi-
bility, but it is unlikely to be as profound as that described
previously (23), given the active division of T cells in the
islets of BDC2.5/NOD tgs (3 and our unpublished data). 
It is necessary to place our results in the context of previ-
ous findings on the influence of CD28/CTLA-4–B7-1/2
interactions on the progression of disease in NOD mice. In
their initial study, Lenschow et al. reported perplexing re-
sults on the effects of anti-B7 reagents (25): mAbs that
block B7-1 or both B7-1 and B7-2 greatly accelerated dia-
betes onset if treatment was begun in the first 2–3 wk of
life and continued for several weeks thereafter. An anti–
B7-2 mAb or a soluble CTLA-4 fusion protein capable of
blocking both B7-1 and B7-2 inhibited disease when given
according to the same protocol. None of the anti-B7 re-
agents had an effect when administered after 10 wk of age.
Matters became even more confusing with a subsequent re-
port on tg mice expressing the soluble B7-1/2 blocker in
the blood from birth and “knockout” animals genetically
incapable of expressing CD28 (32); in both cases, diabetes
was greatly accelerated. It is difficult to amalgamate these
findings into a coherent picture, and even harder to inte-
grate them with our results. Clearly, the complexity of the
CD28/CTLA-4–B7-1/2 system, with its variable patterns
of inducible and constitutive expression and widely ranging
affinities of interaction, demands punctual interventions
with specific reagents during discrete time windows. 
The striking results we obtained no doubt reflect the
simplicity of the BDC2.5 model, in particular, the relative
synchrony of early disease events. Demonstrating an analo-
gous role for CTLA-4 at disease onset in standard NOD
mice and eventually humans, with their more variable dis-
ease courses, will be significantly more challenging. Prelim-
inary results on NOD mice indicate that diabetes can be in-
duced by injection of anti–CTLA-4 mAb at early ages but
that, as expected, the results are less consistent (Lühder, F.,
D. Mathis, and C. Benoist, unpublished data).
 
Figure 3.
 
Treatment with anti–CTLA-4 does not provoke global T cell activation but enhances the aggressiveness of insulitis. (
 
A
 
) Lymphocytes from
the spleen, mesenteric lymph nodes, or pancreas of 17-d-old BDC2.5/NOD mice, after injection with either control mAb (
 
left
 
) or anti–CTLA-4 (
 
right
 
)
on day 12, were stained for CD4, CD8, and CD69 or CD62L. The profiles depict cells gated for CD4 positivity. The bars indicate positive staining. (
 
B
 
)
Representative pancreas sections from BDC2.5/NOD transgenics treated with control mAb (
 
left
 
) or anti–CTLA-4 (
 
right
 
). (
 
Top
 
) Injections on days 2, 5,
and 8 and pancreas removal on day 11. (
 
Bottom
 
) Injections on days 9, 12, and 15 and pancreas removal on day 17.
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